Document Detail


Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients.
MedLine Citation:
PMID:  21499281     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this 12-week prospective observational study, a total of 175 patients aged ≥40 years with International Prostate Symptom Scores (IPSS) ≥12 points and prostate volume ≥20 ml were prospectively enrolled. The patients were divided into two groups according to BMI or WC. Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4 mg once per day for 12 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Q(max)), post-void residual volume, quality of life (QoL) scores and adverse events (AEs) were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven patients had BMI >23 kg m⁻², and 43 had WC >90 cm. Obese patients represented by WC >90 cm or BMI ≥23 kg m⁻² had a significantly greater prostate volume compared with non-obese patients at baseline. Total IPSS was significantly higher in the WC >90 cm group compared to the WC ≤90 cm group. Total IPSS was positively correlated with prostate volume (P=0.031) and WC (P=0.045). All groups showed significant improvements in total IPSS and QoL at 12 weeks. However, the improvement of total IPSS was greater in the high-BMI and high-WC groups. The most frequent AE was dizziness (n=13), and it was significantly lower in the obese BPH patients. Obesity was associated with increased prostate volume and lower urinary tract symptoms. Alpha-blockers appear to be efficacious for controlling symptoms, especially in obese men.
Authors:
Seung Hwan Lee; Cheol Young Oh; Kyung Kgi Park; Mun Su Chung; Se Jeong Yoo; Byung Ha Chung
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-04-18
Journal Detail:
Title:  Asian journal of andrology     Volume:  13     ISSN:  1745-7262     ISO Abbreviation:  Asian J. Androl.     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-09-05     Completed Date:  2011-12-27     Revised Date:  2013-09-17    
Medline Journal Info:
Nlm Unique ID:  100942132     Medline TA:  Asian J Androl     Country:  China    
Other Details:
Languages:  eng     Pagination:  728-31     Citation Subset:  IM    
Affiliation:
Department of Urology, Yonsei University Health System, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-1 Receptor Antagonists / administration & dosage,  therapeutic use
Body Mass Index
Case-Control Studies
Doxazosin / administration & dosage,  therapeutic use
Humans
Male
Obesity / physiopathology*
Prospective Studies
Prostatic Hyperplasia / drug therapy*,  physiopathology
Chemical
Reg. No./Substance:
0/Adrenergic alpha-1 Receptor Antagonists; 74191-85-8/Doxazosin
Comments/Corrections
Comment In:
J Urol. 2012 Oct;188(4):1235   [PMID:  22971392 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic pros...
Next Document:  Small molecule inhibitors of amyloid ? peptide aggregation as a potential therapeutic strategy for A...